Bio-TechneRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Bio-Techne (TECH) reported revenue of $321.00M in Q2 2026, with Consumables its largest revenue segment at 87%.
Bio-TechneSells biological reagents, protein-analysis instruments, and diagnostic and spatial-biology products. Agreed in June 2026 to be acquired by Merck KGaA for $73 per share.
Bio-Techne (TECH) is a Life Sciences Tools & Services company. Sells biological reagents, protein-analysis instruments, and diagnostic and spatial-biology products. Agreed in June 2026 to be acquired by Merck KGaA for $73 per share. It was founded in 1976, is headquartered in Minneapolis, Minnesota and employs about 3,000 people.
As of 2026-Q2, Bio-Techne's revenue breaks down across Consumables (87%), Instruments (11%), Royalty (2%). See the revenue-by-segment chart for the full mix.
Track Bio-Techne's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated October 10, 2026.
Sterling groups Bio-Techne in the Healthcare industry, alongside Revvity (RVTY), Agilent Technologies (A), Charles River Laboratories (CRL), Danaher Corporation (DHR), IQVIA (IQV) and Mettler Toledo (MTD).
If you are researching Bio-Techne, also look at Revvity (RVTY), Agilent Technologies (A) and Charles River Laboratories (CRL). You can compare all of them side by side or browse the full Healthcare industry on Sterling.
Q3 2016-Q2 2026
Q3 2016-Q2 2026